AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome

Recruitingn/aAges 12 Years - 70 YearsAllBeijing Tiantan Hospital
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This multicenter prospective observational cohort study aims to develop and validate individualized risk prediction models for stroke and cognitive decline in patients with moyamoya disease or moyamoya syndrome by integrating clinical characteristics, laboratory data, multimodal neuroimaging, genetic information, and other available multidimensional data. Approximately 3,000 participants will be enrolled and followed for up to 24 months.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria 1. Age 12 to 70 years. 2. Diagnosis of moyamoya disease or moyamoya syndrome by DSA, CTA or MRA. 3. Ability to complete neurological and cognitive assessments. 4. Ability to complete at least 12 months of clinical follow-up and willingness, in principle, to complete 24 months of follow-up. 5. At least one analyzable baseline vascular imaging examination in original DICOM format, including CTA, MRA, or DSA. 6. Written informed consent provided by the participant and/or legally authorized representative. Exclusion Criteria 1. Refusal to participate or inability to complete follow-up. 2. Pregnancy or breastfeeding. 3. Coexisting cerebrovascular malformation, intracranial tumor, hydrocephalus, or another disorder that may independently affect stroke or cognitive outcomes. 4. Severe visual impairment, aphasia, impaired consciousness, psychiatric illness, or another disorder that prevents valid cognitive assessment, including Alzheimer's disease, Parkinson's disease, or frontotemporal dementia. 5. Cardiac conditions that may cause cardioembolic stroke, including atrial fibrillation, patent foramen ovale or other right-to-left shunting cardiac disease, intracardiac mural thrombus, or infective endocarditis; or severe hepatic or renal dysfunction, coagulation disorders, malignancy, or severe cardiopulmonary disease. 6. Receipt of an investigational drug or device within 30 days before screening, or current participation in another interventional clinical trial that may interfere with this study. 7. Previous cerebral revascularization surgery.
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

13 sites
Xuanwu Hospital, Capital Medical University
Beijing, China
Beijing Tiantan Hospital
Beijing, China
Peking Union Medical College Hospital
Beijing, China
The First Medical Center, Chinese PLA General Hospital
Beijing, China
Henan Provincial People's Hospital
Zhengzhou, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Zhongnan Hospital of Wuhan University
Wuhan, China
The First Affiliated Hospital of Soochow University
Suzhou, China

โ€ฆand 5 more on ClinicalTrials.gov.

๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy